Neumora Therapeutics, Inc. 8-K

What Happened

• Neumora Therapeutics, Inc. announced via Form 8-K (filed Feb 11, 2026) that it furnished a corporate presentation it plans to use in meetings with investors and analysts at the Guggenheim Emerging Outlook: Biotech Summit 2026. The presentation is included in the filing as Exhibit 99.1. The filing was signed by Michael Milligan, Chief Financial Officer.

Key Details

• Filing date: February 11, 2026 (Form 8-K).
• Item reported: 7.01 Regulation FD Disclosure — presentation furnished for investor/analyst meetings.
• Exhibit included: 99.1 (Corporate Presentation, dated February 2026); Exhibit 104 (Cover Page Interactive Data File).
• No financial results, earnings, or executive changes were reported in this filing (the filing covers disclosure of the presentation only).

Why It Matters

• This 8-K lets investors know Neumora is publicly sharing its latest corporate presentation and messaging at a major biotech investor conference. The presentation (Exhibit 99.1) is the primary source for any updates on strategy, pipeline highlights, or corporate outlook disclosed there.
• Because the filing is a Regulation FD disclosure, the company is making the material available to ensure broad, fair public access. Investors should review Exhibit 99.1 directly for details before making decisions.